The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Astellas Pharma; AstraZeneca; Janssen-Cilag
Speakers' Bureau - Amgen; Astellas Pharma; AstraZeneca; Bayer; Ferring; ipsen; Janssen; Sanofi
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - ipsen; Janssen; Sanofi
Other Relationship - Astellas Pharma
Proliferation index and survival in men with prostate cancer starting long-term androgen deprivation therapy in the STAMPEDE clinical trial.
 
Larissa Mendes
No Relationships to Disclose
 
Christopher D. Brawley
Research Funding - Astellas Pharma (Inst); Clovis Oncology (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
 
Emily Grist
No Relationships to Disclose
 
Adnan Ali
No Relationships to Disclose
 
Sara Santos Vidal
No Relationships to Disclose
 
Marina Parry
No Relationships to Disclose
 
Sharanpreet Lall
No Relationships to Disclose
 
Nafisah B. Atako
No Relationships to Disclose
 
Sofeya Ishaq
No Relationships to Disclose
 
Malissa Richmond
No Relationships to Disclose
 
Aine Haran
No Relationships to Disclose
 
Alex Hoyle
No Relationships to Disclose
 
Leila Zakka
No Relationships to Disclose
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Noel W. Clarke
No Relationships to Disclose
 
Mahesh K. B. Parmar
No Relationships to Disclose
 
Nicholas D. James
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Clovis Oncology; EUSA pharma; Janssen; pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; Ferring; Janssen Oncology; Merck; Pierre Fabre; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Janssen; Sanofi
 
Louise C. Brown
No Relationships to Disclose
 
Daniel Berney
No Relationships to Disclose
 
Gerhardt Attard
Honoraria - Astellas Pharma; Janssen; Janssen (I)
Consulting or Advisory Role - Abbott Laboratories; Astellas Pharma; AstraZeneca; Bayer; ESSA; Ferring; Janssen-Cilag; Medivation; Millennium; Novartis; Pfizer; Ventana Medical Systems; Veridex
Speakers' Bureau - Astellas Pharma; AstraZeneca; Ferring; Ipsen; Janssen; Sanofi; Takeda; Ventana Medical Systems
Research Funding - Arno Therapeutics (Inst); Innocrin Pharma (Inst); Janssen (Inst)
Patents, Royalties, Other Intellectual Property - I am on The ICR rewards to inventors list of abiraterone acetate.
Travel, Accommodations, Expenses - Abbott Laboratories; Astellas Pharma; Astellas Pharma (I); Bayer; ESSA; Ferring; Janssen; Janssen (I); Medivation; Pfizer; Ventana Medical Systems
Other Relationship - Institute of Cancer Research